Dual inhibition of PI3K and mTOR by NVP-BEZ-235 is promising and should be further evaluated in clinical trials for patients with NSCLC alone and in combination with EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.